Delivery Order #75N91026F00024

Leidos Biomedical Delivery Order for iPSC-Derived Cell Model Development

This award is a delivery order contract issued to Leidos Biomedical Research, Inc., a subsidiary of Leidos Holdings, Inc., recognized for its biomedical research expertise. The contract focuses on the implementation and characterization of induced pluripotent stem cell (iPSC)-derived cell and organoid models to be integrated into new approach methodologies (NAMs), which are innovative techniques aimed at improving biomedical research and reducing reliance on traditional testing methods. This work is significant as it supports advanced research capabilities with potential applications in drug development and toxicology, thereby contributing to public health advancements. The scope encompasses developing and validating these sophisticated cellular models over a multi-year timeframe. The contract was awarded under the umbrella of an existing Federally Funded Research and Development Center (FFRDC) agreement with the National Cancer Institute, highlighting its foundational role in ongoing cancer and biomedical research programs. The award was made through a competitive bidding process, adhering to federal procurement standards. It is set to be performed in Frederick, Maryland, and spans a substantial timeframe, underscoring the long-term commitment to this research initiative.

Description

IMPLEMENTATION AND CHARACTERIZATION OF IPSC-DERIVED CELL AND ORGANOID MODELS FOR INTEGRATION INTO NEW APPROACH METHODOLOGIES (NAMS)

View original record